v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Alliance revenues $ 9,266 $ 8,388 $ 7,582
Total revenues [1] 62,579 63,627 59,553
Cost of sales [2],[3] (16,067) (17,851) (24,954)
Selling, informational and administrative expenses [2] (13,794) (14,730) (14,771)
Product [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues 51,663 53,816 50,914
Royalty [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues 1,650 1,423 1,058
Collaborative Arrangement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Alliance revenues [4] 9,266 8,388 7,582
Total revenues 10,546 9,486 8,400
Cost of sales [5] (2,181) (2,901) (4,277)
Selling, informational and administrative expenses [6] (324) (335) (267)
Research and development expenses [7] 145 282 219
Collaborative Arrangement [Member] | Product [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues [8] 150 175 212
Collaborative Arrangement [Member] | Royalty [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenues—Revenues [9] $ 1,130 $ 923 $ 605
[1] Revenues are primarily attributed to countries based on the location of the customer.
[2] Exclusive of amortization of intangible assets.
[3] See Note 17A.
[4] Substantially all relates to amounts earned from our partners under co-promotion agreements.
[5] Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners.
[6] Represents net reimbursements to our partners for SI&A expenses incurred.
[7] Represents net reimbursements from our partners for R&D expenses incurred.
[8] Represents sales to our partners of products manufactured by us.
[9] Primarily relates to royalties from our collaboration partners.